M Ventures invests in innovative technologies and products with the potential to significantly impact Merck‘s core business areas.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 14, 2022
Storm Therapeutics
|
Series B | $30M | Biotechnology | Yes |
Feb 25, 2021
Medisafe
|
Series C | $30M | Health Care | — |
Jul 14, 2020
iOnctura
|
Series A | €5.10M | Biotechnology | — |
Jan 23, 2020
iOnctura
|
Series A | €15M | Biotechnology | — |
May 20, 2019
Storm Therapeutics
|
Series A | £14M | Biotechnology | — |